Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure.

Cancer chemotherapy and pharmacology - 1 Jul 2024

Malhi Vikram, Nowicka Malgorzata, Chen Ya-Chi, Agarwal Priya, Waldvogel Marie, Lien Yi Ting Kayla, Hafner Marc, Perez-Moreno Pablo, Moore Heather M, Yu Jiajie

Abstract excerpt

PURPOSE: Giredestrant is a potent, orally bioavailable, small-molecule selective estrogen receptor antagonist and degrader (SERD) that is being developed for the treatment of patients with estrogen receptor (ER)-positive breast cancer. In vitro, giredestrant was primarily metabolized by UGT1A4. The goal of this study was to investigate if UGT1A4 polymorphism had a clinically relevant impact on giredestrant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Frequency

Share to Genotype

Share to Glucuronosyltransferase

Share to Haplotypes

Share to Polymorphism, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 38305868
DOI: 10.1007/s00280-023-04634-4
PMCID: PMC11258046

Genes

UGT1A4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure.PMID 38305868Read ↗

Pharmacogenomics of third-generation aromatase inhibitors.Semantic proximity Read ↗

Pre-Therapeutic UGT1A1 Genotyping in Breast Cancer Patients Receiving Sacituzumab Govitecan to Improve Safety: A Meta-Analysis and Recommendation.Semantic proximity Read ↗

UGT1A1 Testing in Breast Cancer: should it become routine practice in patients treated with antibody-drug conjugates?Semantic proximity Read ↗

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.Semantic proximity Read ↗

Influence of glutathione-S-transferase polymorphisms on the metabolism of the potent aromatase inhibitor, exemestaneSemantic proximity Read ↗

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer.Semantic proximity Read ↗

Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer.Semantic proximity Read ↗

Human CYP2A6 Is Induced by Estrogen via Estrogen ReceptorSemantic proximity Read ↗

Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo.Semantic proximity Read ↗

Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer.Semantic proximity Read ↗

Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases.Semantic proximity Read ↗

Impact of combined UGT2B17 and GSTA1 genotypes on exemestane pharmacogenetics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.